Silexion Therapeutics Corp (NASDAQ:SLXN) Shares Shorted: Short Interest Up 1,964.4% in September

Silexion Therapeutics Corp (NASDAQ:SLXN) saw a large growth in short interest during the month of September. As of September 30th, there was short interest totaling 4,925,958 shares, a growth of 1,964.4% from the September 15th total of 238,617 shares. Based on an average daily volume of 40,442,760 shares, the days-to-cover ratio is currently 0.1 days. Approximately 89.3% of the company’s stock are short sold.

Analyst Ratings Changes

Several brokerages have recently issued reports on SLXN. Weiss Ratings reiterated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Friday, September 11th. Maxim Group downgraded shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold”.

Silexion Therapeutics Price Performance

Shares of Silexion Therapeutics stock traded down $0.02 during trading on Friday, hitting $0.21. 790,060 shares of the company’s stock traded hands, compared to its average volume of 3,474,559. Silexion Therapeutics has a 1 year low of $0.21 and a 1 year high of $40.70. The business has a 50-day simple moving average of $0.54 and a 200-day simple moving average of $3.88. The stock has a market capitalization of $1.19 million, a P/E ratio of -0.01 and a beta of -0.29.

Silexion Therapeutics (NASDAQ:SLXN) last issued its earnings results on Saturday, August 15th. The company reported ($5.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($21.20) by $16.03. On average, equities analysts predict that Silexion Therapeutics will post -4.70 earnings per share for the current fiscal year.

About Silexion Therapeutics

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is a clinical-stage biotechnology company focused on developing targeted treatments for cancer, with an emphasis on tumors driven by mutations in the KRAS gene. The company’s primary focus is pancreatic cancer, a disease in which KRAS mutations are common and historically difficult to treat.

Silexion is developing RNA-based therapies designed to suppress cancer-promoting KRAS activity. Its pipeline has included siG12D-LODER, a locally administered therapy intended to deliver small interfering RNA against the KRAS G12D mutation, and SIL-204, a next-generation formulation designed to support broader or systemic delivery of KRAS-targeting treatment.

The company originated in Israel and has conducted its research and clinical development activities through Israeli and international collaborations and clinical programs.